-
1
-
-
84904545875
-
Secukinumab in plaque psoriasis – results of two phase 3 trials
-
Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
-
(2014)
N Engl J Med
, vol.371
, pp. 326-338
-
-
Langley, R.G.1
Elewski, B.E.2
Lebwohl, M.3
-
2
-
-
84949096255
-
Interleukin 17-A inhibition in the treatment of psoriasis
-
Yiu ZZ, Griffiths CE. Interleukin 17-A inhibition in the treatment of psoriasis. Expert Rev Clin Immunol 2016; 12:1–4.
-
(2016)
Expert Rev Clin Immunol
, vol.12
, pp. 1-4
-
-
Yiu, Z.Z.1
Griffiths, C.E.2
-
4
-
-
84939440636
-
To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis
-
Ahn CS, Dothard EH, Garner ML et al. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol 2015; 73:420–8.
-
(2015)
J Am Acad Dermatol
, vol.73
, pp. 420-428
-
-
Ahn, C.S.1
Dothard, E.H.2
Garner, M.L.3
-
5
-
-
84963854339
-
Risk factors for targeted fungal and mycobacterial infections in patients taking tumor necrosis factor inhibitors
-
Salt E, Wiggins AT, Rayens MK et al. Risk factors for targeted fungal and mycobacterial infections in patients taking tumor necrosis factor inhibitors. Arthritis Rheumatol 2016; 68:597–603.
-
(2016)
Arthritis Rheumatol
, vol.68
, pp. 597-603
-
-
Salt, E.1
Wiggins, A.T.2
Rayens, M.K.3
-
6
-
-
79959210742
-
Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy
-
Ruhnke M, Rickerts V, Cornely OA et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 2011; 54:279–310.
-
(2011)
Mycoses
, vol.54
, pp. 279-310
-
-
Ruhnke, M.1
Rickerts, V.2
Cornely, O.A.3
-
8
-
-
84877800182
-
Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment
-
Picciani BLS, Michalski-Santos B, Carneiro S et al. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. J Am Acad Dermatol 2013; 68:986–91.
-
(2013)
J Am Acad Dermatol
, vol.68
, pp. 986-991
-
-
Picciani, B.L.S.1
Michalski-Santos, B.2
Carneiro, S.3
-
9
-
-
84864359374
-
Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy
-
Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther 2012; 14:217.
-
(2012)
Arthritis Res Ther
, vol.14
, pp. 217
-
-
Huppler, A.R.1
Bishu, S.2
Gaffen, S.L.3
-
10
-
-
84939463415
-
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
-
Thaçi D, Blauvelt A, Reich K et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015; 73:400–9.
-
(2015)
J Am Acad Dermatol
, vol.73
, pp. 400-409
-
-
Thaçi, D.1
Blauvelt, A.2
Reich, K.3
-
11
-
-
84925356093
-
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
-
Papp K, Menter A, Strober B et al. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2015; 72:e1.
-
(2015)
J Am Acad Dermatol
, vol.72
-
-
Papp, K.1
Menter, A.2
Strober, B.3
-
12
-
-
84949759880
-
Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials
-
Gottlieb AB, Langley RG, Philipp S et al. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. J Drugs Dermatol 2015; 14:821–33.
-
(2015)
J Drugs Dermatol
, vol.14
, pp. 821-833
-
-
Gottlieb, A.B.1
Langley, R.G.2
Philipp, S.3
-
13
-
-
84915805860
-
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
-
Ohtsuki M, Morita A, Abe M et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 2014; 41:1039–46.
-
(2014)
J Dermatol
, vol.41
, pp. 1039-1046
-
-
Ohtsuki, M.1
Morita, A.2
Abe, M.3
-
14
-
-
84969406048
-
Improvement in psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory with brodalumab treatment in patients with psoriatic arthritis
-
Mease PJ, Genovese MC, Mutebi A et al. Improvement in psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory with brodalumab treatment in patients with psoriatic arthritis. J Rheumatol 2016; 43:343–9.
-
(2016)
J Rheumatol
, vol.43
, pp. 343-349
-
-
Mease, P.J.1
Genovese, M.C.2
Mutebi, A.3
-
15
-
-
84988039700
-
A prospective phase 3, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
-
Papp KA, Reich K, Paul C et al. A prospective phase 3, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175:273–86.
-
(2016)
Br J Dermatol
, vol.175
, pp. 273-286
-
-
Papp, K.A.1
Reich, K.2
Paul, C.3
-
16
-
-
84942876148
-
Phase 3 studies comparing brodalumab with ustekinumab in psoriasis
-
Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373:1318–28.
-
(2015)
N Engl J Med
, vol.373
, pp. 1318-1328
-
-
Lebwohl, M.1
Strober, B.2
Menter, A.3
-
17
-
-
84937972700
-
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)
-
Mrowietz U, Leonardi CL, Girolomoni G et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015; 73:e1.
-
(2015)
J Am Acad Dermatol
, vol.73
-
-
Mrowietz, U.1
Leonardi, C.L.2
Girolomoni, G.3
-
18
-
-
84937984975
-
Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
-
Thaçi D, Humeniuk J, Frambach Y et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol 2015; 173:777–87.
-
(2015)
Br J Dermatol
, vol.173
, pp. 777-787
-
-
Thaçi, D.1
Humeniuk, J.2
Frambach, Y.3
-
19
-
-
84929629144
-
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
-
Paul C, Lacour J-P, Tedremets L et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 2015; 29:1082–90.
-
(2015)
J Eur Acad Dermatol Venereol
, vol.29
, pp. 1082-1090
-
-
Paul, C.1
Lacour, J.-P.2
Tedremets, L.3
-
20
-
-
84922933349
-
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
-
Blauvelt A, Prinz JC, Gottlieb AB et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015; 172:484–93.
-
(2015)
Br J Dermatol
, vol.172
, pp. 484-493
-
-
Blauvelt, A.1
Prinz, J.C.2
Gottlieb, A.B.3
-
21
-
-
84942891597
-
Secukinumab Inhibition of interleukin-17A in patients with psoriatic arthritis
-
Mease PJ, McInnes IB, Kirkham B et al. Secukinumab Inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015; 373:1329–39.
-
(2015)
N Engl J Med
, vol.373
, pp. 1329-1339
-
-
Mease, P.J.1
McInnes, I.B.2
Kirkham, B.3
-
22
-
-
84942198180
-
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
-
McInnes IB, Mease PJ, Kirkham B et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386:1137–46.
-
(2015)
Lancet
, vol.386
, pp. 1137-1146
-
-
McInnes, I.B.1
Mease, P.J.2
Kirkham, B.3
-
23
-
-
84873168729
-
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study
-
Rich P, Sigurgeirsson B, Thaci D et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168:402–11.
-
(2013)
Br J Dermatol
, vol.168
, pp. 402-411
-
-
Rich, P.1
Sigurgeirsson, B.2
Thaci, D.3
-
24
-
-
84977760286
-
Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis
-
van der Heijde D, Landewé RB, Mease PJ et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol 2016; 68:1914–21.
-
(2016)
Arthritis Rheumatol
, vol.68
, pp. 1914-1921
-
-
van der Heijde, D.1
Landewé, R.B.2
Mease, P.J.3
-
25
-
-
84985920039
-
Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study
-
Imafuku S, Honma M, Okubo Y et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol 2016; 43:1011–7.
-
(2016)
J Dermatol
, vol.43
, pp. 1011-1017
-
-
Imafuku, S.1
Honma, M.2
Okubo, Y.3
-
26
-
-
84984999085
-
Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study
-
Kavanaugh A, McInnes IB, Mease PJ et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol 2016; 43:1713–7.
-
(2016)
J Rheumatol
, vol.43
, pp. 1713-1717
-
-
Kavanaugh, A.1
McInnes, I.B.2
Mease, P.J.3
-
27
-
-
84891740105
-
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
-
McInnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73:349–56.
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 349-356
-
-
McInnes, I.B.1
Sieper, J.2
Braun, J.3
-
28
-
-
84925226246
-
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
-
Papp K, Leonardi C, Menter A et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 2014; 71:e3.
-
(2014)
J Am Acad Dermatol
, vol.71
-
-
Papp, K.1
Leonardi, C.2
Menter, A.3
-
29
-
-
84955327621
-
Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study
-
Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci 2015; 81:44–52.
-
(2015)
J Dermatol Sci
, vol.81
, pp. 44-52
-
-
Nakagawa, H.1
Niiro, H.2
Ootaki, K.3
-
30
-
-
84859017988
-
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis
-
Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181–9.
-
(2012)
N Engl J Med
, vol.366
, pp. 1181-1189
-
-
Papp, K.A.1
Leonardi, C.2
Menter, A.3
-
31
-
-
84902209516
-
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis
-
Mease PJ, Genovese MC, Greenwald MW et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014; 370:2295–306.
-
(2014)
N Engl J Med
, vol.370
, pp. 2295-2306
-
-
Mease, P.J.1
Genovese, M.C.2
Greenwald, M.W.3
-
32
-
-
84859073115
-
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis
-
Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190–9.
-
(2012)
N Engl J Med
, vol.366
, pp. 1190-1199
-
-
Leonardi, C.1
Matheson, R.2
Zachariae, C.3
-
33
-
-
84977071601
-
Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis
-
Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375:345–56.
-
(2016)
N Engl J Med
, vol.375
, pp. 345-356
-
-
Gordon, K.B.1
Blauvelt, A.2
Papp, K.A.3
-
34
-
-
84919783193
-
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
-
Gordon KB, Leonardi CL, Lebwohl M et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 2014; 71:1176–82.
-
(2014)
J Am Acad Dermatol
, vol.71
, pp. 1176-1182
-
-
Gordon, K.B.1
Leonardi, C.L.2
Lebwohl, M.3
-
35
-
-
84929630475
-
Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis
-
Saeki H, Nakagawa H, Ishii T et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2015; 29:1148–55.
-
(2015)
J Eur Acad Dermatol Venereol
, vol.29
, pp. 1148-1155
-
-
Saeki, H.1
Nakagawa, H.2
Ishii, T.3
-
36
-
-
84940438565
-
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis
-
Langley RG, Rich P, Menter A et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2015; 29:1763–70.
-
(2015)
J Eur Acad Dermatol Venereol
, vol.29
, pp. 1763-1770
-
-
Langley, R.G.1
Rich, P.2
Menter, A.3
-
37
-
-
79960094057
-
STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis
-
van de Veerdonk FL, Plantinga TS, Hoischen A et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011; 365:54–61.
-
(2011)
N Engl J Med
, vol.365
, pp. 54-61
-
-
van de Veerdonk, F.L.1
Plantinga, T.S.2
Hoischen, A.3
-
38
-
-
79961154447
-
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis
-
Liu L, Okada S, Kong X-F et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011; 208:1635–48.
-
(2011)
J Exp Med
, vol.208
, pp. 1635-1648
-
-
Liu, L.1
Okada, S.2
Kong, X.-F.3
-
39
-
-
84937695151
-
IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans
-
Conti HR, Gaffen SL. IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol 2015; 195:780–8.
-
(2015)
J Immunol
, vol.195
, pp. 780-788
-
-
Conti, H.R.1
Gaffen, S.L.2
-
40
-
-
84876117810
-
C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways
-
Plato A, Willment JA, Brown GD. C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways. Int Rev Immunol 2013; 32:134–56.
-
(2013)
Int Rev Immunol
, vol.32
, pp. 134-156
-
-
Plato, A.1
Willment, J.A.2
Brown, G.D.3
-
41
-
-
84941732206
-
Delinking CARD9 and IL-17: CARD9 protects against Candida tropicalis infection through a TNF-α-dependent, IL-17-independent mechanism
-
Whibley N, Jaycox JR, Reid D et al. Delinking CARD9 and IL-17: CARD9 protects against Candida tropicalis infection through a TNF-α-dependent, IL-17-independent mechanism. J Immunol 2015; 195:3781–92.
-
(2015)
J Immunol
, vol.195
, pp. 3781-3792
-
-
Whibley, N.1
Jaycox, J.R.2
Reid, D.3
-
42
-
-
68849084891
-
Structure and signalling in the IL-17 receptor family
-
Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9:556–67.
-
(2009)
Nat Rev Immunol
, vol.9
, pp. 556-567
-
-
Gaffen, S.L.1
-
43
-
-
84913595693
-
Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis
-
Taheri Sarvtin M, Shokohi T, Hajheydari Z et al. Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis. Int J Dermatol 2014; 53:e555–60.
-
(2014)
Int J Dermatol
, vol.53
, pp. e555-e560
-
-
Taheri Sarvtin, M.1
Shokohi, T.2
Hajheydari, Z.3
-
44
-
-
84979742694
-
A clinician's guide to the diagnosis and treatment of candidiasis in patients with psoriasis
-
Armstrong AW, Bukhalo M, Blauvelt A. A clinician's guide to the diagnosis and treatment of candidiasis in patients with psoriasis. Am J Clin Dermatol 2016; 17:329–36.
-
(2016)
Am J Clin Dermatol
, vol.17
, pp. 329-336
-
-
Armstrong, A.W.1
Bukhalo, M.2
Blauvelt, A.3
-
45
-
-
84938992082
-
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
-
Griffiths CEM, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386:541–51.
-
(2015)
Lancet
, vol.386
, pp. 541-551
-
-
Griffiths, C.E.M.1
Reich, K.2
Lebwohl, M.3
-
46
-
-
84990238873
-
Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study
-
Yamasaki K, Nakagawa H, Kubo Y et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol 2017; 176:741–51.
-
(2017)
Br J Dermatol
, vol.176
, pp. 741-751
-
-
Yamasaki, K.1
Nakagawa, H.2
Kubo, Y.3
-
47
-
-
84914811284
-
Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014
-
Chen SC, Sorrell TC, Chang CC et al. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern Med J 2014; 44:1315–32.
-
(2014)
Intern Med J
, vol.44
, pp. 1315-1332
-
-
Chen, S.C.1
Sorrell, T.C.2
Chang, C.C.3
-
49
-
-
84900829814
-
Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp
-
Arendrup MC, Cuenca-Estrella M, Lass-Flörl CHW. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Update 2013; 16:81–95.
-
(2013)
Drug Resist Update
, vol.16
, pp. 81-95
-
-
Arendrup, M.C.1
Cuenca-Estrella, M.2
Lass-Flörl, C.H.W.3
-
50
-
-
84959876270
-
Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America
-
Pappas PG, Kauffman CA, Andes DR et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1–50.
-
(2016)
Clin Infect Dis
, vol.62
, pp. e1-50
-
-
Pappas, P.G.1
Kauffman, C.A.2
Andes, D.R.3
-
51
-
-
84867691302
-
ECSMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS
-
Lortholary O, Petrikkos G, Akova M et al. ECSMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 2012; 18(Suppl. 7):68–77.
-
(2012)
Clin Microbiol Infect
, vol.18
, pp. 68-77
-
-
Lortholary, O.1
Petrikkos, G.2
Akova, M.3
|